Universal Influenza Vaccine Company Vivaldi Biosciences
Forms Agreement with BlueSky Vaccines for Virus Purification Technologies

FORT COLLINS, Colorado and VIENNA, Austria – July 18, 2019 – Vivaldi Biosciences Inc., a clinical-stage company developing the DeltaFLU universal influenza vaccine, has executed an agreement with BlueSky Vaccines GmbH granting Vivaldi an exclusive option on patent rights to BlueSky's virus purification technologies in the field of live attenuated influenza vaccines (LAIVs) generated by deletion of the gene for nonstructural protein 1 (NS1), a virulence factor of influenza. The two companies expect to execute a definitive license agreement on the purification technologies within a year.

Vivaldi's DeltaFLU universal influenza vaccine is a self-adjuvanting vaccine administered by nasal spray. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for NS1 and optimized for high growth and efficient production in Vero cells. Deletion of NS1 confers the unique and broadly protective mechanism of action of DeltaFLU and ensures the vaccine is safely attenuated.

NS1, produced by disease-causing (wild-type) influenza viruses, blocks the body's production of interferon, a key component of the immune system's response to viral infection. Lacking the ability to produce NS1, DeltaFLU rapidly induces interferon and broadly neutralizing antibodies in the nasal passages, creating a first line of defense directly at the point of entry of circulating viruses. The self-adjuvanting effect of interferon also creates a second line of defense by stimulating the immune system's T cells and antibody-producing B cells to achieve a broadly protective systemic immune response.

Vivaldi has developed a high-efficiency high-yield Vero cell process that enables production of DeltaFLU in just seven weeks. The BlueSky virus purification technologies provide Vivaldi an improved method to produce DeltaFLU with excellent purity and potency, using continuous cell line production at large scale. The technologies were transferred successfully from BlueSky to Vivaldi and used in pilot-scale GMP production of DeltaFLU for forthcoming clinical trials, achieving an overall yield of 80%. Commercial-scale production of live virus vaccines grown in cell culture typically achieves yields of 15% to 30%. The high-yield process translates to a low per-dose cost and opportunity for favorable pricing of Vivaldi's DeltaFLU universal influenza vaccine and vaccines in development for pandemic influenza.

About Vivaldi Biosciences

Vivaldi Biosciences is developing DeltaFLU influenza vaccines for intranasal administration, to provide broad protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU vaccines have been evaluated successfully in four Phase 1 and Phase 2 clinical trials involving a total of 245 adult volunteers. The clinical trials demonstrate the potential for superior efficacy and broad protection against influenza A and B strains with a single dose. These studies also confirm that DeltaFLU vaccine strains are replication-deficient and are not shed by the recipient, providing significant safety advantages. A recent nonclinical study showed that a single dose of DeltaFLU provides protection against distantly drifted influenza strains, and even provides protection against an antigenically shifted influenza strain. Vivaldi Biosciences is based at the Research Innovation Center at Colorado State

University and in Vienna, Austria. NGN Capital LLC is the lead investor in Vivaldi Biosciences. Additional information can be found at www.vivaldibiosciences.com.

Contact:
Bill Wick, CEO, Vivaldi Biosciences
Tel: +1 650-400-8915
bill.wick@vivaldibiosciences.com

Forward-Looking Statements

This release contains forward-looking statements relating to Vivaldi Biosciences, which are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this communication concerning activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the following: the uncertainty of clinical success and of obtaining regulatory approvals, the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, product efficacy or safety concerns resulting in product recalls or regulatory action, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the ability to obtain future funding and to obtain such funding on commercially reasonable terms, the regulatory environment and other risks the Company may identify from time to time in the future. These factors are not necessarily all of the important factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. These forward-looking statements speak only as of the date of this communication and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. This press release should not constitute an offer to sell or a solicitation of an offer to buy securities.